FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1420-1421 September 29, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Waxman, H. A. PubMed Citation

To the Editor: With regard to the Perspective article by Representative Waxman (June 23 issue),¹ Merck initiated the Vioxx Gastrointestinal Outcomes Research (VIGOR) study to evaluate the gastrointestinal safety of Vioxx as compared with naproxen and sought a change in the Food and Drug Administration (FDA) label on the basis of its results. The cardiovascular results of this study were widely discussed on television, in newspapers, and in medical journals. Until the FDA label change, and consistent with Merck's long-standing policies, Merck instructed its sales force not to initiate discussions about VIGOR but to submit physicians' questions about the cardiovascular . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.